157 related articles for article (PubMed ID: 33941865)
21. Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men.
Powell IJ; Vigneau FD; Bock CH; Ruterbusch J; Heilbrun LK
Cancer Epidemiol Biomarkers Prev; 2014 Aug; 23(8):1505-11. PubMed ID: 24802741
[TBL] [Abstract][Full Text] [Related]
22. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.
Howrey BT; Kuo YF; Lin YL; Goodwin JS
J Gerontol A Biol Sci Med Sci; 2013 Jan; 68(1):56-61. PubMed ID: 22562961
[TBL] [Abstract][Full Text] [Related]
23. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
[TBL] [Abstract][Full Text] [Related]
24. Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study.
Abdollah F; Sammon JD; Majumder K; Reznor G; Gandaglia G; Sood A; Hevelone N; Kibel AS; Nguyen PL; Choueiri TK; Selvaggi KJ; Menon M; Trinh QD
J Natl Compr Canc Netw; 2015 Sep; 13(9):1131-8. PubMed ID: 26358797
[TBL] [Abstract][Full Text] [Related]
25. Mining laboratory data to describe prostate specific antigen testing and prostate cancer in Johannesburg, South Africa.
Maphayi MR; Cassim N; Bello B; George JA
Pan Afr Med J; 2020; 35():61. PubMed ID: 32537065
[TBL] [Abstract][Full Text] [Related]
26. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer.
Godley PA; Schenck AP; Amamoo MA; Schoenbach VJ; Peacock S; Manning M; Symons M; Talcott JA
J Natl Cancer Inst; 2003 Nov; 95(22):1702-10. PubMed ID: 14625261
[TBL] [Abstract][Full Text] [Related]
27. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
[TBL] [Abstract][Full Text] [Related]
28. Racial differences in the treatment and outcomes for prostate cancer in Massachusetts.
Cole AP; Herzog P; Iyer HS; Marchese M; Mahal BA; Lipsitz SR; Nyambose J; Gershman ST; Kennedy M; Merriam G; Rebbeck TR; Trinh QD
Cancer; 2021 Aug; 127(15):2714-2723. PubMed ID: 33999405
[TBL] [Abstract][Full Text] [Related]
29. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.
Legler JM; Feuer EJ; Potosky AL; Merrill RM; Kramer BS
Cancer Causes Control; 1998 Oct; 9(5):519-27. PubMed ID: 9934717
[TBL] [Abstract][Full Text] [Related]
30. Race and Time to Receipt of Androgen Deprivation Therapy Among Men With Metastatic Prostate Cancer.
Cobran EK; Young HN; Chen RC; Chen X; Reeves J; Godley PA; Shah S
J Natl Med Assoc; 2019 Jun; 111(3):246-255. PubMed ID: 30389146
[TBL] [Abstract][Full Text] [Related]
31. Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized Prostate Cancer.
Basourakos SP; An A; Davuluri M; Pinheiro LC; Al Awamlh BAH; Borregales LD; Luan D; Tamimi RM; Hu JC; Kensler KH
Urol Pract; 2024 May; 11(3):538-546. PubMed ID: 38640417
[TBL] [Abstract][Full Text] [Related]
32. Racial differences in time from prostate cancer diagnosis to treatment initiation: a population-based study.
Stokes WA; Hendrix LH; Royce TJ; Allen IM; Godley PA; Wang AZ; Chen RC
Cancer; 2013 Jul; 119(13):2486-93. PubMed ID: 23716470
[TBL] [Abstract][Full Text] [Related]
33. Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial.
Landy R; Houghton LC; Berg CD; Grubb RL; Katki HA; Black A
Cancer Prev Res (Phila); 2020 Apr; 13(4):367-376. PubMed ID: 31996370
[TBL] [Abstract][Full Text] [Related]
34. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
35. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
Mahal BA; Yang DD; Wang NQ; Alshalalfa M; Davicioni E; Choeurng V; Schaeffer EM; Ross AE; Spratt DE; Den RB; Martin NE; Mouw KW; Orio PF; Choueiri TK; Taplin ME; Trinh QD; Feng FY; Nguyen PL
Eur Urol; 2018 Aug; 74(2):146-154. PubMed ID: 29478736
[TBL] [Abstract][Full Text] [Related]
36. Racial disparities in changing to a high-volume urologist among men with localized prostate cancer.
Pollack CE; Bekelman JE; Epstein AJ; Liao K; Wong YN; Armstrong K
Med Care; 2011 Nov; 49(11):999-1006. PubMed ID: 22005606
[TBL] [Abstract][Full Text] [Related]
37. Association of black race with follow-up of an abnormal prostate-specific antigen test.
Turner BJ; Mavandadi S; Weiner MG
J Natl Med Assoc; 2011 Feb; 103(2):150-7. PubMed ID: 21443067
[TBL] [Abstract][Full Text] [Related]
38. Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level < 4 ng/ml: a population-based study.
Zheng Z; Zhou Z; Yan W; Zhou Y; Chen C; Li H; Ji Z
BMC Cancer; 2020 Apr; 20(1):340. PubMed ID: 32321456
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?
Valberg M; Grotmol T; Tretli S; Veierød MB; Moger TA; Devesa SS; Aalen OO
Eur J Epidemiol; 2017 Jun; 32(6):511-520. PubMed ID: 27431530
[TBL] [Abstract][Full Text] [Related]
40. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
